Free Trial

CRISPR Therapeutics (CRSP) Competitors

CRISPR Therapeutics logo
$41.36 +0.08 (+0.19%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$41.32 -0.03 (-0.08%)
As of 06/13/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CRSP vs. NBIX, EXEL, MRNA, QGEN, TECH, RVMD, RGEN, HALO, ADMA, and PCVX

Should you be buying CRISPR Therapeutics stock or one of its competitors? The main competitors of CRISPR Therapeutics include Neurocrine Biosciences (NBIX), Exelixis (EXEL), Moderna (MRNA), Qiagen (QGEN), Bio-Techne (TECH), Revolution Medicines (RVMD), Repligen (RGEN), Halozyme Therapeutics (HALO), ADMA Biologics (ADMA), and Vaxcyte (PCVX). These companies are all part of the "biological products, except diagnostic" industry.

CRISPR Therapeutics vs. Its Competitors

CRISPR Therapeutics (NASDAQ:CRSP) and Neurocrine Biosciences (NASDAQ:NBIX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 4.3% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 4.8% of Neurocrine Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Neurocrine Biosciences received 559 more outperform votes than CRISPR Therapeutics when rated by MarketBeat users. Likewise, 77.70% of users gave Neurocrine Biosciences an outperform vote while only 64.29% of users gave CRISPR Therapeutics an outperform vote.

CompanyUnderperformOutperform
CRISPR TherapeuticsOutperform Votes
486
64.29%
Underperform Votes
270
35.71%
Neurocrine BiosciencesOutperform Votes
1045
77.70%
Underperform Votes
300
22.30%

CRISPR Therapeutics currently has a consensus price target of $71.75, suggesting a potential upside of 73.48%. Neurocrine Biosciences has a consensus price target of $162.00, suggesting a potential upside of 30.24%. Given CRISPR Therapeutics' higher probable upside, equities research analysts clearly believe CRISPR Therapeutics is more favorable than Neurocrine Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CRISPR Therapeutics
1 Sell rating(s)
7 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.50
Neurocrine Biosciences
0 Sell rating(s)
3 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.86

Neurocrine Biosciences has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISPR Therapeutics$35M102.06-$366.25M-$4.52-9.15
Neurocrine Biosciences$2.41B5.10$341.30M$2.9542.17

In the previous week, Neurocrine Biosciences had 9 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 22 mentions for Neurocrine Biosciences and 13 mentions for CRISPR Therapeutics. Neurocrine Biosciences' average media sentiment score of 1.05 beat CRISPR Therapeutics' score of 0.95 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CRISPR Therapeutics
6 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Neurocrine Biosciences
11 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Neurocrine Biosciences has a net margin of 14.49% compared to CRISPR Therapeutics' net margin of -981.54%. Neurocrine Biosciences' return on equity of 13.38% beat CRISPR Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISPR Therapeutics-981.54% -18.46% -15.79%
Neurocrine Biosciences 14.49%13.38%9.73%

CRISPR Therapeutics has a beta of 1.75, suggesting that its stock price is 75% more volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500.

Summary

Neurocrine Biosciences beats CRISPR Therapeutics on 15 of the 18 factors compared between the two stocks.

Get CRISPR Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRSP vs. The Competition

MetricCRISPR TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$3.57B$3.09B$5.57B$8.51B
Dividend YieldN/A1.56%5.27%4.16%
P/E Ratio-9.4632.6326.7519.65
Price / Sales102.06455.18404.17152.19
Price / CashN/A168.6838.2534.64
Price / Book1.843.366.964.59
Net Income-$366.25M-$72.35M$3.23B$248.23M
7 Day Performance-1.19%0.36%-1.23%-1.07%
1 Month Performance13.91%16.10%6.34%2.59%
1 Year Performance-34.93%-15.37%33.04%13.50%

CRISPR Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRSP
CRISPR Therapeutics
3.2947 of 5 stars
$41.36
+0.2%
$71.75
+73.5%
-34.9%$3.57B$35M-9.46473Analyst Revision
Gap Down
NBIX
Neurocrine Biosciences
4.9109 of 5 stars
$126.00
+0.5%
$162.00
+28.6%
-8.2%$12.47B$2.41B38.291,200Positive News
Analyst Revision
EXEL
Exelixis
4.3863 of 5 stars
$42.96
-0.2%
$39.35
-8.4%
+91.3%$11.71B$2.30B24.261,220Positive News
Analyst Forecast
MRNA
Moderna
4.4523 of 5 stars
$28.30
+3.1%
$53.58
+89.3%
-81.0%$10.93B$3.14B-3.053,900Trending News
Options Volume
Gap Down
QGEN
Qiagen
3.3157 of 5 stars
$46.30
+1.8%
$48.42
+4.6%
+14.4%$10.29B$2.00B128.946,030
TECH
Bio-Techne
4.8557 of 5 stars
$50.10
+2.9%
$72.00
+43.7%
-33.4%$7.86B$1.21B50.643,000Gap Down
RVMD
Revolution Medicines
4.422 of 5 stars
$40.99
-0.2%
$67.08
+63.7%
+5.1%$7.63B$742K-11.41250Positive News
RGEN
Repligen
4.7293 of 5 stars
$132.29
+3.1%
$173.25
+31.0%
+1.5%$7.47B$650.43M-260.802,020Gap Down
HALO
Halozyme Therapeutics
4.8738 of 5 stars
$54.63
+0.7%
$61.90
+13.3%
+9.1%$6.73B$1.08B15.92390
ADMA
ADMA Biologics
2.3471 of 5 stars
$21.06
+2.2%
$24.25
+15.1%
+95.8%$5.05B$459.38M75.50530Positive News
Insider Trade
Analyst Revision
PCVX
Vaxcyte
3.1544 of 5 stars
$37.30
+0.8%
$136.50
+266.0%
-52.6%$4.80BN/A-8.09160Positive News
Analyst Revision
Gap Down

Related Companies and Tools


This page (NASDAQ:CRSP) was last updated on 6/15/2025 by MarketBeat.com Staff
From Our Partners